Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Mon, 19.08.2024
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
H1/24 results
Recommendation:
Buy
from:
19.08.2024
Target price:
€80
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analy [ … ]
Tue, 06.08.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon AG increases its outlook for the 2024 fiscal year
Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t [ … ]
Tue, 30.07.2024
Formycon AG
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab)
The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries [ … ]
Fri, 26.07.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Planegg-Martinsried, Germany, July 26, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the Committee for Medicinal Products for Human Use („CHMP“) of the Eu [ … ]
Fri, 28.06.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Fri, 28.06.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Thu, 13.06.2024
Formycon AG
First Berlin Equity Research has published a research update on Formycon AG
(ISIN: DE000A1EWVY8). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 105.00 to EUR 80.00.
Abstract:
The Formycon share price has fallen by more than 40% since the beginning of
2023, mainly because of lower than expected royalty i [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In).
"Dah [ … ]
Wed, 08.05.2024
Formycon AG
Press Release // May 8, 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Group revenue amounts to € 17.7 million and corresponds to plan
Group EBITDA of € -5.5 million reflects investments in pipeline and corporate development
Adjusted Group EBITDA of € -1.2 million shows strong at-equi [ … ]
Tue, 07.05.2024
Formycon AG
Press release // 07 May 2024
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members
With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial [ … ]